IFNA1 and myeloid sarcoma: Furthermore, since type I IFN has also been approved for MS (15), essential thrombocythemia (ET) (16), and other myeloproliferative diseases, systematic evaluation of all information about IFN exposure during pregnancy would provide a comprehensive safety profile for hepatologists.